Kaya Hacer Kayhan, Demirtas Berjan
Department of Physiology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey.
Equine and Training Program, Plant and Animal Production Department, Vocational School of Veterinary Medicine, İstanbul University-Cerahpaşa, İstanbul, Turkey.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3977-3984. doi: 10.1007/s00210-024-03517-6. Epub 2024 Oct 9.
Statins may affect glucose metabolism through adipokines. The aim of this study was to measure the effects of hydrophilic statins on the levels of several adipokines in diabetic rats. Wistar albino rats were divided into four groups: healthy control, untreated diabetic, diabetic treated with pravastatin, and diabetic treated with rosuvastatin. Diabetes was induced by intraperitoneal injection of STZ. Thereafter, 20 mg/kg/day doses of either pravastatin or rosuvastatin were administered to the treated diabetic rats for 8 weeks. At the end of the experiment, the body weights, fasting blood glucose levels, serum insulin levels, and insulin resistance, as well as the serum adiponectin, leptin, visfatin, and vaspin levels, were measured. Fasting blood glucose and insulin resistance levels were significantly higher, whereas insulin levels and body weight were significantly lower in the untreated diabetic group than in the control group. Diabetes caused significant decreases in adiponectin, leptin, and vaspin levels but a significant increase in visfatin levels. Pravastatin treatment significantly increased body weight and decreased fasting blood glucose levels, whereas rosuvastatin decreased body weight but did not affect fasting blood glucose levels. Pravastatin caused significant increases in both adiponectin and vaspin levels. However, rosuvastatin did not affect the adiponectin level but caused a significant decrease in the vaspin levels. Both pravastatin and rosuvastatin treatments decreased the leptin and visfatin levels. In conclusion, pravastatin is more effective at improving fasting blood glucose levels and body weight in diabetic rats, probably by increasing adiponectin and vaspin levels.
他汀类药物可能通过脂肪因子影响葡萄糖代谢。本研究的目的是测定亲水性他汀类药物对糖尿病大鼠几种脂肪因子水平的影响。将Wistar白化大鼠分为四组：健康对照组、未治疗的糖尿病组、普伐他汀治疗的糖尿病组和瑞舒伐他汀治疗的糖尿病组。通过腹腔注射链脲佐菌素诱导糖尿病。此后，给治疗的糖尿病大鼠每日服用20mg/kg剂量的普伐他汀或瑞舒伐他汀，持续8周。实验结束时，测量体重、空腹血糖水平、血清胰岛素水平和胰岛素抵抗，以及血清脂联素、瘦素、内脂素和内脏脂肪素水平。未治疗的糖尿病组空腹血糖和胰岛素抵抗水平显著高于对照组，而胰岛素水平和体重显著低于对照组。糖尿病导致脂联素、瘦素和内脏脂肪素水平显著降低，但内脂素水平显著升高。普伐他汀治疗显著增加体重并降低空腹血糖水平，而瑞舒伐他汀降低体重但不影响空腹血糖水平。普伐他汀使脂联素和内脏脂肪素水平均显著升高。然而，瑞舒伐他汀不影响脂联素水平，但使内脏脂肪素水平显著降低。普伐他汀和瑞舒伐他汀治疗均降低了瘦素和内脂素水平。总之，普伐他汀在改善糖尿病大鼠空腹血糖水平和体重方面更有效，可能是通过增加脂联素和内脏脂肪素水平实现的。
